Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.

Arun Azad,Arnauld Villers,Boris Alekseev,Russell Z. Szmulewitz,Antonio Alcaraz,Neal D. Shore,Daniel P. Petrylak,Jeffrey M. Holzbeierlein,Francisco Gómez Veiga,Brad Rosbrook,Fabian Zohren,Ho-Jin Lee,Gabriel P. Haas,Taro Iguchi,Arnulf Stenzl,Andrew J. Armstrong

Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.

2021

Arun Azad
Arnauld Villers
Boris Alekseev
Russell Z. Szmulewitz
Antonio Alcaraz
Neal D. Shore
Daniel P. Petrylak
Jeffrey M. Holzbeierlein
Francisco Gómez Veiga
Brad Rosbrook
Fabian Zohren
Ho-Jin Lee
Gabriel P. Haas
Taro Iguchi
Arnulf Stenzl
Andrew J. Armstrong

102Background: In ARCHES (NCT02677896) ENZA + ADT reduced the risk of radiographic progression-free survival (rPFS) events, primary endpoint, and improved key secondary endpoints vs PBO + ADT in me...

Keywords:

Oncology
Clinical endpoint
Androgen deprivation therapy
Medicine
Post-hoc analysis
Internal medicine
Hormone sensitive prostate cancer
Enzalutamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations